Halyard Health (NYSE:HYH) said late last month it tapped former Acelity prez & CEO Joseph Woody as its new chief executive officer, replacing a retiring Robert Abernathy. Woody will also assume a seat on the board of directors, with former CEO Abernathy continuing on as board chair, the Alpharetta, Ga.-based company said. “On behalf of the […]
SOLOS Endoscopy Inc.
American Medical Group picks up controlling interest in Solos Endoscopy
UPDATE: Includes new information on CEO Segersten’s resignation Solos Endoscopy said last Friday that the American Medical Group has acquired a controlling interest in the company from Solos’ president, Bob Segersten. The Boston-based company said that, in connection with the acquisition of shares, American Medical Group prez Dom Gatto will join Solos Endoscopy’s board of […]
World Heart’s 2011 sales go negative | Earnings roundup
Ortho market growth stable but low | Wall Street Beat
The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.
Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion’s share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector’s outlook calls for low-single-digit growth.
Ortho stocks up on strong Q2 prelims for Biomet | Earnings Roundup
Shares of orthopedic device makers are up this morning after bellwether Biomet Inc. reported preliminary sales numbers indicating 3.8% growth for its fiscal second quarter.
Accuray slips into the red in Q4, FY2011 | Earnings Roundup
Accuray Inc. (NSDQ:ARAY) may be the fish that swallowed the whale, but it might have bitten off more than it can chew judging from its fourth-quarter and fiscal 2011 results.
The Sunnyvale, Calif.-based radiosurgery device maker paid $300 million for its larger rival TomoTherapy in March. That acquisition sent ARAY into the red for both the quarter and full year.
Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
BOSTON, Sept. 15, 2011 /PRNewswire/ — Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company has shown a 32% increase in Breast Endoscopy sales for the period of June through August 2011 as compared to the prior year. Management recently reported an increase in demand for its new MammoView® instrument line.
Solos Endoscopy aims to cut debt in the face of declining sales
Solos Endoscopy Inc. (PINK:SNDY) aims to reduce some of its debt through consummated agreements that will cut more than $620,000 of its debt for the period ending September 30.
The Boston, Mass.-based company posted a 19 percent decrease in sales for the quarter ended June 30, although it managed to narrow its losses to $186,360, or a loss of 2 cents per share, compared to $229,973 lost, or 82 cents lost per diluted share in Q2 of 2010.
Fresenius sees sales and earnings rise in Q2 | Earnings Roundup
Fresenius Medical Care AG (NYSE:FMS) posted a healthy quarter with growth in sales and earnings driven by a 26 percent bump in international sales.
"We are particularly pleased with the success of our international region, given a persistently challenging business environment with the current debt crisis worldwide and the successful expansion of our clinic network in Asia-Pacific and Europe," CEO Dr. Ben Lipps said in prepared remarks.
Endoscopy goes to the multi-billion dollar dogs
MASSDEVICE ON CALL — Solos Endoscopy Inc. (PINK:SNDY) announced that it has launched its revamped veterinary product line of endoscopic equipment, scopes and instruments.
Veterinary endoscopy involves minimally invasive techniques for performing procedures through natural holes in the body rather than through large incisions.
The American Pet Products Assn. estimates that consumers spent more than $45 billion on pets in 2009, and more than $12 billion was on veterinary care.
